Content about Allergen immunotherapy

April 18, 2014

Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U).

WHITEHOUSE STATION, N.J. — Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U). Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis. Ragwitek is approved for use in adults ages 18 years through 65 years. 

April 2, 2014

Greer Labs, a developer and provider of allergy immunotherapy products and services, announced that the Food and Drug Administration has approved Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablet.

LENOIR, N.C. — Greer Labs, a developer and provider of allergy immunotherapy products and services, announced that the Food and Drug Administration has approved Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablet.

May 8, 2013

Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

WHITEHOUSE STATION, N.J. — Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

Merck said the Food and Drug Administration accepted a regulatory application for its ragweed pollen sublingual allergy immunotherapy tablet. Ragweed, also known as Ambrosia artemisiifolia, is a major cause of seasonal allergies in the United States. Merck also submitted an application for a similar drug, for Timothy grass pollen allergies, in March.

August 16, 2012

According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

ARLINGTON HEIGHTS, Ill. — According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

July 30, 2012

While most people treat nasal allergy symptoms, they often ignore their itchy, red, watery eyes. According to the Asthma and Allergy Foundation of America, approximately 40 million Americans have indoor/outdoor allergies as their primary allergy, and approximately 4% of allergy sufferers have eye allergies as their primary allergy. 


Already with a strong pedigree across eye care and ear care, Similasan recently launched its Kids Irritated Eye Relief for multisymptom relief from redness, burning, stinging and grittiness.

May 16, 2012

In contrast to the most recent cough-cold season, which was characterized by a relative lack of upper respiratory illnesses, pharmacy shoppers with itchy eyes, runny noses and audible sneezes have been back in force this spring in search of allergy relief.

In contrast to the most recent cough-cold season, which was characterized by a relative lack of upper respiratory illnesses, pharmacy shoppers with itchy eyes, runny noses and audible sneezes have been back in force this spring in search of allergy relief. And those patients are gravitating toward the OTC aisle for their seasonal allergy needs now that the last of the second-generation antihistamines was made available without a prescription a year ago. 


May 10, 2011

Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

HORSHAM, Pa. — Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

March 22, 2011

Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

SAN FRANCISCO — Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.